Central African Gold Inc
Change company Symbol lookup
Select an option...
NDENF Central African Gold Inc
HD Home Depot Inc
ACPS AC Partners Inc
FONR Fonar Corp
WBRRFX BlackRock Russell 2000 Growth Index Fund
WSM Williams-Sonoma Inc
BLK BlackRock Inc
TSEM Tower Semiconductor Ltd
CG Carlyle Group Inc
WDAY Workday Inc
Go

Materials : Metals & Mining | Small Cap Blend
Based in Canada
Company profile

Central African Gold Inc, formerly Bankers Cobalt Corp, is a Canada-based natural resource company. The Company focuses on the acquisition, exploration, development, and operation of mineral projects in the Democratic Republic of the Congo (DRC). The Company’s exploration projects seek copper and cobalt in the DRC. It holds rights to approximately nine mineral projects located in the southern DRC CopperBelt. The Company also focuses to acquire interests in additional concessions.

Closing Price
$0.3136
Day's Change
-0.0014 (-0.44%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.3136
Day's Low
0.2836
Volume
(Heavy Day)
Volume:
20,250

10-day average volume:
5,430
20,250

Everything you need to know about what it would take for the FDA to approve a COVID-19 vaccine

5:19 pm ET September 22, 2020 (MarketWatch)
Print

By WILLIAM PETRI

A top medical researcher explains how we would know if a vaccine is safe and effective

With COVID-19 vaccines currently in the final phase of study, you've probably been wondering how the Food and Drug Administration will decide if a vaccine is safe and effective.

Based on the status of the Phase 3 trials (https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html) currently under way, it is unlikely that the results of these trials will be available before November. But it is likely that not just one but several of the competing COVID-19 vaccines will be shown to be safe and effective by the end of 2020.

I am a scientist and infectious diseases specialist (https://scholar.google.com/citations?hl=en&user=6yMIM1MAAAAJ&view_op=list_works&sortby=pubdate) at the University of Virginia, where I care for patients with COVID-19 and conduct research on the pandemic. I am also a member of the World Health Organization Expert Group on COVID-19 Vaccine Prioritization.

Phase 3 studies are under way (https://partners.mediasite.com/mediasite/Play/968f633a874c4f1a80c368496f49d4661d) for the Moderna (MRNA) and BioNTech (BNTX) /Pfizer (PFE) vaccines and the Oxford/AstraZeneca (AZN.LN) viral vector vaccine.

Follow the latest news on the coronavirus on MarketWatch (https://www.marketwatch.com/economy-politics/coronavirus?mod=home-page)

Each of these vaccines uses the SARS-CoV-2 spike glycoprotein, which the virus uses to infect cells, to trigger the immune system to generate protective antibodies and a cellular immune response to the virus. Protective antibodies act by preventing the spike glycoprotein from attaching the virus to human cells, thereby neutralizing the SARS-CoV-2 virus that causes COVID-19.

In the case of Moderna's nucleic acid vaccine (https://theconversation.com/coronavirus-a-new-type-of-vaccine-using-rna-could-help-defeat-covid-19-133217), the messenger RNA encoding the spike glycoprotein is encased in a fat droplet--called a liposome--to protect the mRNA from degradation and enable it to enter cells. Once these instructions are inside the cells, the mRNA is read by the human cell machinery and made into many spike proteins so that the immune system can respond and begin producing antibodies against this coronavirus.

The Oxford/AstraZeneca uses a different strategy to activate an immune response. Here an adenovirus found in chimpanzees shuttles the instructions for manufacturing the spike glycoprotein into cells.

Phase 1 and 2 studies (http://doi.org/10.1126/science.abc5312) by the pharmaceutical companies Janssen and Merck (MRK) also use viral vectors similar to the Oxford/AstraZeneca vaccine, while vaccines by Novavax (NVAX) and GSK (GSK.LN) and Sanofi (SAN.FR) use the actual spike protein itself.

Studies in animal models of COVID-19 provide convincing evidence that vaccination with the spike glycoprotein will protect from COVID-19. Experiments have show that when the immune system is shown the spike protein--which alone cannot trigger disease--the immune system will generate an antibody response that protects from infection with SARS-CoV-2.

In studies in hamsters (https://doi.org/10.1038/s41591-020-1070-6) an adenovirus viral vector--the approach used by Oxford/AstraZeneca, for example--was used to immunize with the spike glycoprotein. When the hamsters were infected with SARS-CoV-2 they were protected from pneumonia, weight loss and death.

In nonhuman primates (http://doi.org/10.1126/science.abc6284), DNA vaccines--which deliver the gene for the spike glycoprotein--reduced the amount of virus in the lungs. Animals that produced an antibody that prevented virus attachment to human cells were most likely to be protected.

Overall, vaccination has triggered a more potent neutralizing antibody response (https://www.nejm.org/doi/full/10.1056/NEJMoa2026920?query=featured_coronavirus) than even that seen in patients recovering from COVID-19.

This has also been the case for Moderna's vaccine currently in Phase 3 trials (http://doi.org/10.1056/NEJMoa2022483) and for vaccines from CanSino Biologics (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31611-1/fulltext) and Oxford/ AstraZeneca (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31611-1/fulltext).

Physicians have recorded (https://doi.org/10.1016/S0140-6736(20)31605-6) mild to moderate reactions (https://doi.org/10.1016/S0140-6736(20)31604-4) when the subjects were observed (http://doi.org/10.1056/NEJMoa2022483) up to 28 days after vaccination. These side effects included mild pain, warmth and tenderness at the site of injection, and fever, fatigue, joint and muscle pain.

But Phase 1 and 2 studies are by small by design, with just hundreds of participants. So these trials will not be large enough to detect uncommon or rare side effects.

The emphasis on safety as the primary goal was recently demonstrated in the Phase 3 Oxford/AstraZeneca vaccine trial where one vaccinated individual developed inflammation of the spinal cord (https://www.nature.com/articles/d41586-020-02594-w). It isn't clear whether the vaccine caused this reaction--it might be a new case of multiple sclerosis unrelated to the vaccine--but the Phase 3 trial was halted in the U.S. until more is known.

The FDA has issued guidance for industry (https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-and-licensure-vaccines-prevent-covid-19) on the steps required for developing and ultimately licensing vaccines to prevent COVID-19--these are the same rigorous safety standards required for all vaccines.

There are, however, ways to speed the process of approval that are centered on "platform technology."

What this means is that if a vaccine is using an approach such as an adenovirus that has previously been shown to be safe, it may be possible for a company to use previously collected data on toxicity and pharmacokinetics to fast-track clinical trial approval.

ile speed and safety may appear conflicting goals, it is also encouraging to note that the rival vaccine manufacturers have jointly pledged (http://Drug companies to issue joint pledge on safety, standards to bolster confidence in COVID-19 vaccine) not to bow to any political pressures to rush vaccine approval, but to maintain the most rigorous safety standards.

The FDA has set the bar for the primary endpoint of a Phase 3 trial of 50% protection for approval of a COVID-19 vaccine.

Protection is defined as protection from symptomatic COVID-19 infection, defined as laboratory-confirmed SARS-CoV-2 infection plus symptoms such as fever or chills, cough, shortness of breath, fatigue, muscle aches, loss of taste or smell, congestion or runny nose, diarrhea, nausea or vomiting.

This means that an effective vaccine is considered one that will reduce the number of infections in vaccine recipients by half. This is the minimal protection that is anticipated to be clinically useful (https://doi.org/10.1016/S0140-6736(20)31821-3). That is, in part, because lower levels of efficacy could paradoxically increase COVID-19 infections if it leads vaccinated people to decrease mask wearing or social distancing because they think they are completely protected.

Since a vaccine might be more effective at preventing severe COVID-19, the FDA instructs that protection from severe COVID-19 (https://www.fda.gov/media/139638/download) should be a secondary endpoint.

FDA to announce tough guidelines that could delay approval of vaccine, Washington Post reports (https://www.washingtonpost.com/health/2020/09/22/fda-covid-vaccine-approval-standard/)

The current Phase 3 trials are enrolling 30,000-40,000 subjects. Most of these participants will receive the vaccine and some a placebo.

When, exactly, the results of Phase 3 studies will be released depends in large part on the rate of infection in the placebo recipients. The way that these vaccine studies work is that they test if naturally acquired new coronavirus infections are lower in the group that received the vaccine compared with the group receiving the placebo.

So while it is good news that COVID-19 infections have dropped recently in the U.S. from 70,000 to 40,000 cases per day (https://www.nytimes.com/interactive/2020/us/coronavirus-us-cases.html?auth=login-email&login=email), this drop in new infections may slow the vaccine studies.

In an emergency such as we are faced with the COVID-19 pandemic, with approximately 700 new deaths and 40,000 new cases per day right now, the FDA is authorized to allow the use of unapproved products for the diagnosis, treatment and prevention of disease. That includes a vaccine.

The standard approval process for vaccines (https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-and-licensure-vaccines-prevent-covid-19) can require more than one year of observation after vaccination. If the short-term safety is good and the vaccine works to prevent COVID-19, then the vaccine should be approved for use under an Emergency Use Authorization while it is still being studied.

Under Emergency Use Authorization, the FDA will continue to collect information (https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization) from the companies producing the vaccines for benefit and harm, including surveillance for vaccine-associated enhanced respiratory disease or other potentially rare complications that might be observed in only one in a million.

I expect that the FDA will approve several vaccines by the end of 2020 under its Emergency Use Authorization authority so that vaccination can begin immediately, starting with high-risk groups including first responders, health-care personnel, and the elderly and those with pre-existing medical conditions.

(MORE TO FOLLOW) Dow Jones Newswires

September 22, 2020 17:19 ET (21:19 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.